Euro vs US Dollar

Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.

Registrieren

PASG Passage Bio Inc

0,5764

0,00 (0,00%)

30 Jan 2025 - Geschlossen

Verzögert um 15 Minuten

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Article too big to display. Click here to view on the SEC website

Passage Bio (NASDAQ:PASG)
Historical Stock Chart
Von Dez 2024 bis Jan 2025

Click Here for more Passage Bio Charts.

Passage Bio (NASDAQ:PASG)
Historical Stock Chart
Von Jan 2024 bis Jan 2025

Click Here for more Passage Bio Charts.

News Passage Bio Inc

Form 8-K - Current report
Freitag 10 Januar 2025 (3 Wochen vor) • Edgar (US Regulatory)

Passage Bio Announces Interim Data from upliFT-D Study in FTD-GRN and Provides Business Updates
Freitag 10 Januar 2025 (3 Wochen vor) • GlobeNewswire Inc.

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
Donnerstag 14 November 2024 (3 Monate vor) • Edgar (US Regulatory)

Form SC 13G - Statement of Beneficial Ownership by Certain Investors
Donnerstag 14 November 2024 (3 Monate vor) • Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Mittwoch 13 November 2024 (3 Monate vor) • Edgar (US Regulatory)

Form 8-K - Current report
Mittwoch 13 November 2024 (3 Monate vor) • Edgar (US Regulatory)

Passage Bio Reports Third Quarter 2024 Financial Results and Provides Recent Business Highlights
Mittwoch 13 November 2024 (3 Monate vor) • GlobeNewswire Inc.

Passage Bio to Present at Guggenheim Securities Healthcare Innovation Conference
Mittwoch 6 November 2024 (3 Monate vor) • GlobeNewswire Inc.

Form 8-K - Current report
Donnerstag 24 Oktober 2024 (3 Monate vor) • Edgar (US Regulatory)

Passage Bio Presents Preclinical and Interim Clinical Data for PBFT02 in FTD-GRN at the European Society of Gene & Cell Therapy (ESGCT) 31st Annual Conference
Donnerstag 24 Oktober 2024 (3 Monate vor) • GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities
Mittwoch 2 Oktober 2024 (4 Monate vor) • Edgar (US Regulatory)

Passage Bio to Present at Chardan’s 8th Annual Genetic Medicines Conference
Montag 23 September 2024 (4 Monate vor) • GlobeNewswire Inc.

Weitere Passage Bio Inc News-Artikel

Gemphire Therapeutics

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen